NASDAQ:NEONeoGenomics Stock Price, Forecast & News

NeoGenomics' stock was trading at $24.78 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NEO shares have increased by 36.7% and is now trading at $33.88. View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 1 hold rating, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NeoGenomics.

NeoGenomics is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for NeoGenomics.

NeoGenomics will be holding an earnings conference call on Tuesday, July 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings results on Tuesday, April, 28th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.04. The medical research company earned $106.03 million during the quarter, compared to the consensus estimate of $106.03 million. NeoGenomics had a return on equity of 2.94% and a net margin of 0.82%. The business's revenue for the quarter was up 10.9% on a year-over-year basis. During the same period in the prior year, the company earned ($0.03) EPS. View NeoGenomics' earnings history.

NeoGenomics issued an update on its first quarter 2020 Pre-Market earnings guidance on Thursday, April, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $106-106 million, compared to the consensus revenue estimate of $104.42 million.

10 brokerages have issued 1 year price targets for NeoGenomics' stock. Their forecasts range from $9.00 to $38.00. On average, they expect NeoGenomics' stock price to reach $31.00 in the next year. This suggests that the stock has a possible downside of 8.5%. View analysts' price targets for NeoGenomics.

Headlines about NEO stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. NeoGenomics earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View the latest news about NeoGenomics.

Some companies that are related to NeoGenomics include Straumann (SAUHF), Smith & Nephew (SN), Merck KGaA (MRK), Bio-Rad Laboratories (BIO), SONOVA HLDG AG/ADR (SONVY), Steris (STE), GALAPAGOS NV/S (GLPG), EXACT Sciences (EXAS), Bio-Rad Laboratories (BIO.B), GRIFOLS S A/S (GRFS), Ramsay Health Care Limited Fully Paid Ord. Shrs (RHC), Sarepta Therapeutics (SRPT), Insulet (PODD), Sonic Healthcare (SHL) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology Group (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Micron Technology (MU), Square (SQ), Cisco Systems (CSCO), Inseego (INSG), Advanced Micro Devices (AMD) and Crispr Therapeutics (CRSP).

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NEO stock can currently be purchased for approximately $33.88.

NeoGenomics has a market capitalization of $3.57 billion and generates $408.83 million in revenue each year. The medical research company earns $8.01 million in net income (profit) each year or $0.23 on an earnings per share basis. NeoGenomics employs 1,700 workers across the globe.

The official website for NeoGenomics is www.neogenomics.com.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]